Header Logo

Connection

NICOLA HANANIA to Severity of Illness Index

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Severity of Illness Index.
NICOLA HANANIA
Connection Strength
2.063
Severity of Illness Index
  1. COPD Management in the Primary Care Setting. J Fam Pract. 2018 10; 67(10 Suppl):S27-S32.
    View in: PubMed
    Score: 0.347
  2. Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
    View in: PubMed
    Score: 0.127
  3. Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
    View in: PubMed
    Score: 0.107
  4. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.090
  5. Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
    View in: PubMed
    Score: 0.088
  6. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
    View in: PubMed
    Score: 0.083
  7. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.082
  8. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.081
  9. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
    View in: PubMed
    Score: 0.078
  10. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.073
  11. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.069
  12. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.057
  13. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.056
  14. Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. J Appl Physiol (1985). 2012 Jan; 112(1):42-7.
    View in: PubMed
    Score: 0.054
  15. Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011 Sep; 128(3 Suppl):S4-24.
    View in: PubMed
    Score: 0.053
  16. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J. 2009 Sep; 18(3):198-207.
    View in: PubMed
    Score: 0.046
  17. Asthma control: a new perspective on the management of asthma. Curr Opin Pulm Med. 2009 Jan; 15(1):1-3.
    View in: PubMed
    Score: 0.044
  18. Can we predict depression in COPD? COPD. 2007 Mar; 4(1):3-4.
    View in: PubMed
    Score: 0.039
  19. Revisiting asthma control: how should it best be defined? Pulm Pharmacol Ther. 2007; 20(5):483-92.
    View in: PubMed
    Score: 0.037
  20. The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(4):345-54.
    View in: PubMed
    Score: 0.036
  21. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.032
  22. The impact of fungal allergic sensitization on asthma. Curr Opin Pulm Med. 2021 01; 27(1):3-8.
    View in: PubMed
    Score: 0.025
  23. Bayesian inference of networks across multiple sample groups and data types. Biostatistics. 2020 07 01; 21(3):561-576.
    View in: PubMed
    Score: 0.024
  24. Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. J Asthma. 2021 07; 58(7):849-854.
    View in: PubMed
    Score: 0.024
  25. Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. Contemp Clin Trials. 2020 04; 91:105977.
    View in: PubMed
    Score: 0.024
  26. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018 01; 24(1):50-55.
    View in: PubMed
    Score: 0.021
  27. Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 01; 313(5):R620-R629.
    View in: PubMed
    Score: 0.020
  28. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017 Nov 01; 18(11):955-959.e6.
    View in: PubMed
    Score: 0.020
  29. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.019
  30. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
    View in: PubMed
    Score: 0.019
  31. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.019
  32. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan; 22(1):59-68.
    View in: PubMed
    Score: 0.018
  33. Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respir Med. 2016 Feb; 111:30-8.
    View in: PubMed
    Score: 0.018
  34. A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015; 10:725-38.
    View in: PubMed
    Score: 0.017
  35. Antifungals in severe asthma. Curr Opin Pulm Med. 2015 Jan; 21(1):48-54.
    View in: PubMed
    Score: 0.017
  36. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.017
  37. Racial differences in CT phenotypes in COPD. COPD. 2013 Feb; 10(1):20-7.
    View in: PubMed
    Score: 0.015
  38. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011 Oct; 261(1):274-82.
    View in: PubMed
    Score: 0.013
  39. Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism. 2011 Oct; 60(10):1449-55.
    View in: PubMed
    Score: 0.013
  40. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.013
  41. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
    View in: PubMed
    Score: 0.011
  42. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
    View in: PubMed
    Score: 0.010
  43. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.